TGEN Insider Report: Albertine Awarded 25k Stock Options, 175k Held
Rhea-AI Filing Summary
Form 4 snapshot: On 07/24/2025 Tecogen Inc. (TGEN) granted Director John M. Albertine 25,000 stock options at an exercise price of $8.35. The options vest 25 % per year, first exercisable 07/24/2026 and expiring 07/24/2035.
The award lifts Albertine’s directly held derivative position to 175,000 options. No purchases or sales of common shares were reported and no change was disclosed in non-derivative share ownership. The filing, signed 07/28/2025, appears to be a routine board compensation grant with no immediate cash flow or share-count impact.
Positive
- None.
Negative
- None.
Insights
Routine option grant; aligns director incentives, neutral impact.
The Form 4 discloses a standard equity award to a non-employee director. No cash outlay, no common-share sale, and no dilution until exercised. Size (25 k vs. 175 k cumulative) is modest and typical for board compensation. Vesting over four years encourages long-term focus but does not materially alter insider ownership or control. For investors, this is housekeeping rather than a directional signal.
Neutral for valuation; no immediate share flow.
The 25,000 options are out-of-the-money until TGEN trades above $8.35, leaving near-term EPS and cash untouched. Potential dilution is well under 0.1 % of outstanding shares, immaterial to valuation models. Absent open-market buying or selling, the filing does not shift the risk/reward profile. I classify the event as informational only.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 25,000 | $8.35 | $209K |
Footnotes (1)
- [object Object]